Carregant...
New insights and long-term safety of tocilizumab in rheumatoid arthritis
Rheumatoid arthritis is a leading musculoskeletal cause of disability in Western society. Therapeutic options have expanded rapidly with the advent of biological agents as treatment options. One of these, tocilizumab, targets the interleukin-6 receptor and has been approved since the late 2000s in m...
Guardat en:
| Publicat a: | Ther Adv Musculoskelet Dis |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6178374/ https://ncbi.nlm.nih.gov/pubmed/30327685 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1759720X18798462 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|